OmniAb, Inc. (OABIW) stock
OABIWNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as OABI
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 10/309% above fair value
$0.41−0.01 (-2.38%)
Close on Oct 30, 2026Market cap $742.95MP/E –Yield –
OmniAb operating margin
Operating margin is operating income as a percentage of revenue.
OmniAb's operating margin for the twelve months ending Sep 30, 2026 was -115.9%. For fiscal 2025 it was -369.5%, against -282.3% the year before. The highest annual figure on record is -45.1% in fiscal 2022.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -369.5% | −87.2 |
| FY2024 | Dec 31, 2024 | -282.3% | −79.1 |
| FY2023 | Dec 31, 2023 | -203.2% | −158.1 |
| FY2022 | Dec 31, 2022 | -45.1% | +57.4 |
| FY2021 | Dec 31, 2021 | -102.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -409.9% | +400.3 |
| Q2 FY2026 | Jun 30, 2026 | -49.5% | +366.7 |
| Q1 FY2026 | Mar 31, 2026 | -54.3% | +399.4 |
| Q4 FY2025 | Dec 31, 2025 | -188.2% | −41.2 |
| Q3 FY2025 | Sep 30, 2025 | -810.2% | −336.5 |
| Q2 FY2025 | Jun 30, 2025 | -416.2% | −202.0 |
| Q1 FY2025 | Mar 31, 2025 | -453.6% | +139.7 |
| Q4 FY2024 | Dec 31, 2024 | -147.0% | +292.8 |
| Q3 FY2024 | Sep 30, 2024 | -473.7% | −102.8 |
| Q2 FY2024 | Jun 30, 2024 | -214.1% | +65.8 |
| Q1 FY2024 | Mar 31, 2024 | -593.3% | −543.4 |
| Q4 FY2023 | Dec 31, 2023 | -439.8% | −465.4 |
| Q3 FY2023 | Sep 30, 2023 | -370.9% | −155.2 |
| Q2 FY2023 | Jun 30, 2023 | -279.9% | −105.4 |
| Q1 FY2023 | Mar 31, 2023 | -50.0% | +35.5 |
| Q4 FY2022 | Dec 31, 2022 | 25.6% | – |
| Q3 FY2022 | Sep 30, 2022 | -215.8% | – |
| Q2 FY2022 | Jun 30, 2022 | -174.6% | – |
| Q1 FY2022 | Mar 31, 2022 | -85.5% | – |